Decreased nitric oxide bioavailability in a mouse model of Fabry disease. - Wikidata - awgldk - TriplyDB

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

http://www.wikidata.org/entity/Q37330561

about

The balance of powers: Redox regulation of fibrogenic pathways in kidney injury Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension.Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Multi-system disorders of glycosphingolipid and ganglioside metabolism Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometry Serum high concentrations of homocysteine and low levels of folic acid and vitamin B12 are significantly correlated with the categories of coronary artery diseases Homocysteine and erythrocyte sedimentation rate correlate with cerebrovascular disease in fabry disease.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.An association of metabolic syndrome constellation with cellular membrane caveolae Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.The urea decomposition product cyanate promotes endothelial dysfunction.Glycosphingolipid Mediated Caveolin-1 Oligomerization.Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice.Fabry disease

P2860

Q26786137-E37DD9DF-DD96-4F00-BF51-D751696907FC Q28072656-3EE75F5B-DEC8-4D88-B98C-B8C98CF0DC8A Q28730130-14C72C0E-1703-4EB6-B399-0F93154EBA87 Q30428077-C5D0BEB0-FB1B-400E-8F6B-C5F3F4BEDBC8 Q33726258-B5C2C655-3251-445C-B47F-13755B669267 Q33825097-0A5683D0-056E-4C0B-AA6C-210F05F3EE76 Q33831482-7C699C42-815A-4123-8B5E-1A6421EB8C48 Q33902037-75E6B56C-29B2-4D48-AA4F-81793AE465FE Q34257466-5534255A-1F8A-4F4A-945C-E6D0F1443C6C Q35173711-AAADC22A-2FDC-4787-9FD4-C9F421258FBC Q36256320-53907BCB-6FB5-4FCF-80E3-4A6EF70B5861 Q36590911-4A0E1526-1E62-48AB-86D2-BC003DB7321B Q36808226-152022E4-E0BE-483D-8D11-66783E503F87 Q37575656-7AB2D1DD-3CE4-489A-9F64-FB8CF293B54F Q37589401-15B6D8B3-A411-49B2-8B38-BB66DD11CF28 Q38844401-7A8D4388-C904-4EFD-A961-ED795140EBFA Q40351353-2DDD458C-A3AE-4611-A01C-290B694D1845 Q42025075-38EB80FD-1BF4-4174-821F-8EB3CE7B757E Q42148671-56DC2992-ABC4-490D-A19F-69370A5017B4 Q47123134-1A051EC1-17B0-4090-8CCF-50EC3BAF9052 Q53453652-A3452164-1ED4-4416-BA73-E44BB2EDEAD5 Q53608980-43621148-A573-4675-99EA-CD9D633CB5B0 Q56905945-052ACF17-E1BA-4E30-8187-80F688D4B438

P2860

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

http://www.wikidata.org/entity/Q37330561

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@en

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@nl

type

label

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@en

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@nl

prefLabel

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@en

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@nl

P1433

Q37330561-2E85DB6E-7DE4-4333-9252-F9B0E113F302

P1476

Q37330561-BA9678E9-383A-4B61-8968-F393BCC1074C

P2093

Q37330561-509795CA-66EB-4F77-BA76-1181696EB0D9

Q37330561-56A5055F-E8D7-459A-9E66-C35B54B9F9C9

Q37330561-6A26DA81-A1DB-4610-B7E9-3D67A90E4EBA

Q37330561-6F0D1001-7F2D-4BD7-9D6B-45953C99719D

Q37330561-8B4DA0F4-ABE1-4DBF-812E-D05FC0B34116

Q37330561-AA971E8D-D2DC-409A-9D95-D4504A468B2C

P2860

Q37330561-002DF505-23BC-4EAD-B28A-6050B216A9D0

Q37330561-07D057D7-6075-4459-87D1-F8497AD15A4E

Q37330561-0904D2C2-51B1-4BB4-9EFE-EE171BF0E69F

Q37330561-0E20104D-159A-4FCA-8926-1DCAFE1C7CE6

Q37330561-154906B1-AEAC-4109-81C3-44DE3E71A193

Q37330561-2A715FBC-E896-4E09-B0F1-82602DB754A0

Q37330561-2E1A729B-2772-4106-BC91-4F98BFEC6A88

Q37330561-31157E3F-A6FB-4459-9767-4BE7B05A8501

Q37330561-391D9E1B-37D7-4A9D-9F8F-0FFE2CF006DF

Q37330561-4051CC92-87CB-41E7-A010-2539B3B2F540

P304

Q37330561-816F7361-BACD-46F2-B78F-05673DA1CD14

P31

Q37330561-C7494427-5ACD-49BA-9CCE-3EF750B1ECC7

P356

Q37330561-906F5942-BFBA-4A4E-8376-E69C32722245

P433

Q37330561-20C2DE2D-32DA-4AA4-AD17-0214B11E683A

P478

Q37330561-CB63ED19-B5B9-450E-A859-41502B1638A9

P577

Q37330561-52EDC5B7-A1E0-4C97-81AF-5FFD92BCD9C8

P698

Q37330561-A1A2AE6D-2F37-4AD4-8B38-7505BE2BB16A

P932

Q37330561-D3483DA5-FA41-455E-883E-D80808C0D784

P356

P1433

Journal of the American Society of Nephrology

P1476

Decreased nitric oxide bioavailability in a mouse model of Fabry disease.

@en

P2093

Jaeman Byun

http://www.w3.org/2001/XMLSchema#string

James A Shayman

http://www.w3.org/2001/XMLSchema#string

James L Park

http://www.w3.org/2001/XMLSchema#string

Jessica Kollmeyer

http://www.w3.org/2001/XMLSchema#string

Liming Shu

http://www.w3.org/2001/XMLSchema#string

Subramaniam Pennathur

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of endothelial nitric oxide synthase: location, location, location

A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease

Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation

alpha-Galactosidase A deficient mice: a model of Fabry disease

The membrane-spanning domains of caveolins-1 and -2 mediate the formation of caveolin hetero-oligomers. Implications for the assembly of caveolae membranes in vivo

Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency

Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension

Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth.

Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting

Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage.

P304

1975-1985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2008111190

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19628671

http://www.w3.org/2001/XMLSchema#string

P932

2736776

http://www.w3.org/2001/XMLSchema#string